Novo Nordisk

NVO

Market cap $261B

Novo Nordisk A/S (NOVO:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Novo Nordisk CEO Mike Doustdar said on Tuesday the drugmaker expects headwinds in its international operations in 2026, as competition intensifies after losing market exclusivity in several countries.

NVO jumps nearly 19% in a month primarily on the FDA approval and launch of oral Wegovy, the first GLP-1 pill for obesity and cardiovascular risk reduction.

Eli Lilly and Novo Nordisk make the world's most popular weight loss drugs. These injectable products have generated double-digit growth, with revenue reaching blockbuster levels.

Novo Nordisk launched an oral version of its best-selling weight management medicine. It may not help catch up to Eli Lilly, whose oral anti-obesity drug is also expected to hit the market soon.

Mike Doustdar, Novo Nordisk president and CEO, joins 'Mad Money' host Jim Cramer to talk the success of GLP-1, pricing for weight-loss pills and more.

Mike Doustdar, Novo Nordisk president and CEO, joins 'Mad Money' host Jim Cramer to talk the success of GLP-1, pricing for weight-loss pills and more.

Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026's first half.

Oral weight-loss drugs could make up a third or more of the overall GLP-1 market by 2030, a larger percentage than the company originally anticipated, a Novo Nordisk executive said on Monday.

Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of blockbuster GLP-1 drugs, underscoring how cheaper, unapproved alternatives have captured a significant share of demand for obesity treatments.